<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01546350</url>
  </required_header>
  <id_info>
    <org_study_id>Reprogenetics study 389</org_study_id>
    <secondary_id>Reprogenetics study 389</secondary_id>
    <nct_id>NCT01546350</nct_id>
  </id_info>
  <brief_title>Preimplantation Genetic Diagnosis Using Blastocyst Biopsy and Array CGH</brief_title>
  <official_title>Comparison of Standard ART Practice vs. Trophectoderm Biopsy, Array CGH Analysis, and Day-6 Replacement of a Single Euploid Embryo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reprogenetics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Reprogenetics, Livingston, NJ</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Long Island IVF, Melville, NY</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Reproductive Associates of Illinois, Highland Park, IL</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>McGill University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>BlueGnome, Cambridge, UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Southern California Reproductive Center, CA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Reprogenetics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose to perform a clinical randomized trial to evaluate the effect of
      single embryo (blastocyst) transfer (SET) with array CGH for the evaluation of the complete
      chromosome complement of the blastocyst in comparison to standard ART methods in which one or
      more embryo are replaced. Patients will be randomized into two groups:

        -  Control group: patients will have up to two embryos replaced on day 5 based on
           morphological and developmental characteristics, and the other embryos reaching
           blastocyst stage will be vitrified. If patients in the control group do not have a
           pregnancy to term from that fresh cycle, they will be offered free PGD either for the
           frozen embryos of that cycle or for the next cycle (up to the center and patient). Data
           from that PGD is not part of the study.

        -  Test group: patients will have grade A,B or C blastocysts hatched on day 5, biopsied on
           day 5, analyzed by array CGH, and a single euploid embryo transferred on day 6. Any
           morulas developing to grade A,B or C blastocyst on day-6 will be also analyzed but
           vitrified for use in a future cycle.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomized after fertilization, and will be dropped from the study if they
      produce 3 or less blastocysts on day 5. The Primary efficacy endpoint of comparing the study
      group with the control will be (I) implantation rates and (II) multiple pregnancies (twin or
      higher order) comparing the first transfer.

      The study may be extended to evaluate secondary efficacy endpoints which will be miscarriage
      rate and take home baby rates comparing the two groups.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    not enough patients recruited on time
  </why_stopped>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Implantation rate</measure>
    <time_frame>First month after replacement</time_frame>
    <description>fetal sacs / embryos replaced</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Spontaneous miscarriage rate</measure>
    <time_frame>during first and second trimester of pregnancy</time_frame>
    <description>pregnancies lost / pregnancies of cycles randomized</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ongoing pregnancy rate</measure>
    <time_frame>third trimester of pregnancy</time_frame>
    <description>pregnancies past second trimester / cycles started</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple pregnancy rate</measure>
    <time_frame>first month after transfer</time_frame>
    <description>Twin or multiple order pregnancies / total pregnancies</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Infertility</condition>
  <condition>Recurrent Pregnancy Loss</condition>
  <arm_group>
    <arm_group_label>Control - regular ART treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>patients will have up to two embryos replaced on day 5 based on morphological and developmental characteristics, and the other embryos reaching blastocyst stage will be vitrified. If patients in the control group do not have a pregnancy to term from that fresh cycle, they will be offered free PGD either for the frozen embryos of that cycle or for the next cycle (up to the center and patient). Data from that PGD is not part of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test - PGD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients will have grade A,B or C blastocysts hatched on day 5, biopsied on day 5, analyzed by array CGH, and a single euploid embryo transferred on day 6. Any morulas developing to grade A,B or C blastocyst on day-6 will be also analyzed but vitrified for use in a future cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>PGD</intervention_name>
    <description>array CGH after blastocyst biopsy</description>
    <arm_group_label>Test - PGD</arm_group_label>
    <other_name>PGD: Preimplantation Genetic Diagnosis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PGD</intervention_name>
    <description>PGD using blastocyst biopsy and testing of the biopsy by array CGH</description>
    <arm_group_label>Test - PGD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Maternal age 33 to 42 years old (included)

        Exclusion Criteria:

          -  MESA and TESE patients

          -  At least one partner carrier of a chromosomal or genetic disease

          -  Abnormal ovarian reserve, defined as FSH of &gt;10 IU/L on day 2-4 of the cycle and AMH &lt;
             1ng /ml (If only one of the two parameters altered then patients is acceptable).

          -  Egg donor cycle (sperm donor is acceptable)

        Exclusion criteria during stimulation:

          -  Less than eight antral follicles on day 2-4 of cycle

        Exclusion criteria on day 5 post retrieval:

          -  Patients will be excluded if they produce less than 3 grade A,B or C blastocysts by
             day 5.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>32 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Santiago Munne, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Reprogenetics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southern California Reproductive Center</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>92677</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reproductive Associates of Illinois</name>
      <address>
        <city>Highland Park</city>
        <state>Illinois</state>
        <zip>60035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reprogenetics</name>
      <address>
        <city>Livingston</city>
        <state>New Jersey</state>
        <zip>07039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Island IVF</name>
      <address>
        <city>Melville</city>
        <state>New York</state>
        <zip>11747</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gutiérrez-Mateo C, Colls P, Sánchez-García J, Escudero T, Prates R, Ketterson K, Wells D, Munné S. Validation of microarray comparative genomic hybridization for comprehensive chromosome analysis of embryos. Fertil Steril. 2011 Mar 1;95(3):953-8. doi: 10.1016/j.fertnstert.2010.09.010. Epub 2010 Oct 25.</citation>
    <PMID>20971462</PMID>
  </reference>
  <reference>
    <citation>Cohen J, Wells D, Munné S. Removal of 2 cells from cleavage stage embryos is likely to reduce the efficacy of chromosomal tests that are used to enhance implantation rates. Fertil Steril. 2007 Mar;87(3):496-503. Epub 2006 Dec 4.</citation>
    <PMID>17141767</PMID>
  </reference>
  <reference>
    <citation>Munné S, Wells D, Cohen J. Technology requirements for preimplantation genetic diagnosis to improve assisted reproduction outcomes. Fertil Steril. 2010 Jul;94(2):408-30. doi: 10.1016/j.fertnstert.2009.02.091. Epub 2009 May 5. Review.</citation>
    <PMID>19409550</PMID>
  </reference>
  <reference>
    <citation>Schoolcraft WB, Fragouli E, Stevens J, Munne S, Katz-Jaffe MG, Wells D. Clinical application of comprehensive chromosomal screening at the blastocyst stage. Fertil Steril. 2010 Oct;94(5):1700-6. doi: 10.1016/j.fertnstert.2009.10.015. Epub 2009 Nov 25.</citation>
    <PMID>19939370</PMID>
  </reference>
  <reference>
    <citation>De Vos A, Staessen C, De Rycke M, Verpoest W, Haentjens P, Devroey P, Liebaers I, Van de Velde H. Impact of cleavage-stage embryo biopsy in view of PGD on human blastocyst implantation: a prospective cohort of single embryo transfers. Hum Reprod. 2009 Dec;24(12):2988-96. doi: 10.1093/humrep/dep251. Epub 2009 Sep 21.</citation>
    <PMID>19773223</PMID>
  </reference>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2012</study_first_submitted>
  <study_first_submitted_qc>March 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2012</study_first_posted>
  <last_update_submitted>August 20, 2013</last_update_submitted>
  <last_update_submitted_qc>August 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>infertility, recurrent pregnancy loss, miscarriage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Abortion, Habitual</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

